2025-03-29 18:17:04
Latest Post
Cineline India Ltd monetizes Hotel Asset for INR 270 crores, becomes Net Debt-Free company
Emami Realty Limited appoints Ms. Ishani Ray as additional director
The Ramco Cements Ltd increases cement grinding capacity by 0.4 MTPA
Manappuram Finance Limited board approves fund raising program for FY 2025-26
Adani Renewable Energy Fifty Seven Ltd commissions incremental solar power project of 37.50 MW at Khavda
Stock Report
Zim Laboratories Ltd reports higher consolidated PAT of Rs. 7.23 crores in Q4 FY2023
Posted On : 2023-05-20 11:43:49( TIMEZONE : IST )
Zim Laboratories Ltd has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 106.1050 crores during the period ended March 31, 2023 as compared to Rs. 103.3747 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 7.2364 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 6.6006 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 1.48 for the period ended March 31, 2023 as compared to Rs. 1.35 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹106.1050 crs | ₹103.3747 crs |  2.64% |
| Net Profit | ₹7.2364 crs | ₹6.6006 crs | 9.63% |
| EPS | ₹1.48 | ₹1.35 | 9.63% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.106.1050 crores during the period ended March 31, 2023 as compared to Rs.106.6909 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.7.2364 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.7.0302 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.1.48 for the period ended March 31, 2023 as compared to Rs.1.45 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹106.1050 crs | ₹106.6909 crs |  -0.55% |
| Net Profit | ₹7.2364 crs | ₹7.0302 crs | 2.93% |
| EPS | ₹1.48 | ₹1.45 | 2.07% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.404.9403 crores during the Financial Year ended March 31, 2023 as compared to Rs.337.8295 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.24.4345 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.14.5504 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.5.01 for the Financial Year ended March 31, 2023 as compared to Rs.2.99 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹404.9403 crs | ₹337.8295 crs | 19.87% |
| Net Profit | ₹24.4345 crs | ₹14.5504 crs | 67.93% |
| EPS | ₹5.01 | ₹2.99 | 67.56% |
Shares of Zim Laboratories Ltd was last trading in BSE at Rs. 101.06 as compared to the previous close of Rs. 100.49. The total number of shares traded during the day was 10144 in over 390 trades.
The stock hit an intraday high of Rs. 105.50 and intraday low of 96.00. The net turnover during the day was Rs. 1024602.00.
